Advertisement
Canada markets open in 2 hours 55 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7312
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    82.84
    +0.03 (+0.04%)
     
  • Bitcoin CAD

    86,822.56
    -4,005.04 (-4.41%)
     
  • CMC Crypto 200

    1,356.08
    -26.49 (-1.92%)
     
  • GOLD FUTURES

    2,338.20
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,505.75
    -158.75 (-0.90%)
     
  • VOLATILITY

    16.16
    +0.19 (+1.19%)
     
  • FTSE

    8,089.92
    +49.54 (+0.62%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6812
    -0.0007 (-0.10%)
     

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023?

Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.